… of 3, 4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA …

P Huot, TH Johnston, KD Lewis, JB Koprich… - Journal of …, 2011 - Soc Neuroscience

Author(s): Karl Lewis , James Koprich

Focus: MDMA


l-3, 4-Dihydroxyphenylalanine (l-DOPA) is the most effective treatment for Parkinson9s disease, but long-term l-DOPA administration is marred by the emergence of motor complications, namely, dyskinesia and a shortening of antiparkinsonian benefit (wearing …

Last updated: Jul 27, 2020